Silence Therapeutics Plc (SLN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SLN SEC filings page.
Silence Therapeutics Plc (SLN) reported $615K in revenue over the twelve months to Jun 30, 2026, down 97.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is now development-stage: revenue nearly vanished, while research spending and operating cash use remained substantial.
Between FY2024 and FY2025, revenue fell from$43.3M to$559K , revealing a sharp loss of commercial scale rather than ordinary volatility. Yet R&D remained elevated at$67.8M and operating cash outflow was$62.3M , showing that the cost base is being carried for development work instead of flexing with revenue.
Cash consumption is primarily operating investment: FY2025 free cash flow was
Financing support largely disappeared: financing cash flow fell from
Financial Health Signals
Silence Therapeutics Plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Silence Therapeutics Plc scores -2.00, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($612.8M) relative to total liabilities ($69.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Silence Therapeutics Plc passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Silence Therapeutics Plc reported a net loss of $88.6M while operations used $62.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Silence Therapeutics Plc generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Silence Therapeutics Plc's EBITDA was -$13.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.2% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.
Silence Therapeutics Plc reported -$12.3M in net income in Q2 2026. This represents an increase of 55.2% from the same quarter a year earlier. Against the prior quarter it is up 18.0%.
Silence Therapeutics Plc earned -$0.09 per diluted share (EPS) in Q2 2026. This represents an increase of 52.6% from the same quarter a year earlier. Against the prior quarter it is up 18.2%.
Cash & Balance Sheet
Silence Therapeutics Plc generated $1.5M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 107.0% from the same quarter a year earlier. Against the prior quarter it is up 109.7%.
Silence Therapeutics Plc held $72.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Silence Therapeutics Plc's ROE was -31.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Silence Therapeutics Plc invested $9.1M in research and development in Q2 2026. This represents a decrease of 48.2% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.
Silence Therapeutics Plc reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
SLN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $422K+197.2% | $34K-99.9% | $159K-89.4% | $224K-70.4% | $142K-99.1% | $25.3M | $1.5M |
| Cost of Revenue | $0-100.0% | $11K-79.6% | $12K-99.4% | $64K-98.2% | $85K-97.4% | $54K-98.1% | $2.0M | $3.6M |
| Gross Profit | $0-100.0% | $411K+367.0% | $22K-99.9% | $95K+104.4% | $139K+105.4% | $88K-99.3% | $23.3M | -$2.1M |
| R&D Expenses | $9.1M-48.2% | $9.1M-56.2% | $8.7M-60.4% | $20.5M+1.9% | $17.6M+27.9% | $20.8M+75.7% | $22.1M | $20.2M |
| SG&A Expenses | $4.7M-8.1% | $7.0M-8.6% | $3.7M-32.6% | $5.8M-24.7% | $5.1M-26.8% | $7.7M+15.8% | $5.5M | $7.7M |
| Operating Income | -$13.9M+42.1% | -$15.7M+44.6% | -$12.5M-186.3% | -$26.2M+12.5% | -$24.0M-2.5% | -$28.4M-409.0% | -$4.4M | -$30.0M |
| EBITDA | -$13.8M+42.2% | -$15.7M+44.7% | -$12.4M-189.5% | -$26.2M+12.5% | -$23.9M-2.5% | -$28.3M-415.9% | -$4.3M | -$29.9M |
| Income Tax | $1K-90.0% | $0 | $0-100.0% | $1K-98.0% | $10K-95.6% | $0-100.0% | $324K | $49K |
| Net Income | -$12.3M+55.2% | -$15.0M+47.6% | -$11.8M-195.7% | -$21.0M+41.0% | -$27.4M-38.5% | -$28.5M-1134.0% | $12.3M | -$35.5M |
| EPS (Basic) | -$0.09+52.6% | -$0.11+45.0% | -$0.09-200.0% | -$0.15+40.0% | -$0.19-35.7% | -$0.20-900.0% | $0.09 | -$0.25 |
| EPS (Diluted) | -$0.09+52.6% | -$0.11+45.0% | -$0.09-200.0% | -$0.15+40.0% | -$0.19-35.7% | -$0.20-900.0% | $0.09 | -$0.25 |
| Diluted Shares (Avg) | 142M0.0% | 142M0.0% | N/A | 142M+0.4% | 142M+1.1% | 142M+7.4% | N/A | 141M |
Not reported in any period shown, so not listed: Interest Expense.
SLN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $106.4M-35.6% | $115.1M-37.9% | $131.4M-35.1% | $146.8M | $165.2M | $185.3M | $202.6M+69.6% | N/A |
| Current Assets | $94.3M-36.5% | $102.9M-39.4% | $118.7M-36.7% | $133.6M | $148.6M | $169.8M | $187.4M+81.6% | N/A |
| Cash & Equivalents | $72.1M+72.6% | $5.7M-91.3% | $11.3M-90.7% | $82.0M | $41.7M | $64.9M | $121.3M+76.4% | N/A |
| Short-Term Investments | $0-100.0% | $64.4M-10.1% | $73.8M+183.9% | $20.2M | $72.4M | $71.6M | $26.0M | N/A |
| Accounts Receivable | N/A | $0-100.0% | $0-100.0% | $28K | $85K | $41K | $972K+235.2% | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Goodwill | $10.3M-2.8% | $10.4M-2.5% | $10.6M+13.1% | $10.6M+13.0% | $10.6M | $10.6M+8.8% | $9.4M-5.9% | $9.4M |
| Total Liabilities | $67.9M-4.4% | $65.7M-9.4% | $69.1M+0.8% | $72.7M | $71.1M | $72.6M | $68.6M-29.6% | N/A |
| Current Liabilities | $12.7M-13.9% | $10.5M-45.7% | $13.6M-19.1% | $17.4M | $14.8M | $19.3M | $16.8M-24.7% | N/A |
| Non-Current Liabilities | $55.2M-1.9% | $55.3M+3.7% | $55.5M+7.2% | $55.3M | $56.3M | $53.3M | $51.8M-31.1% | N/A |
| Total Equity | $38.5M-59.1% | $49.4M-56.2% | $62.3M-53.5% | $74.1M-41.5% | $94.2M-33.9% | $112.7M-28.1% | $134.0M+509.4% | $126.7M |
| Retained Earnings | -$589.6M-11.3% | -$577.5M-14.9% | -$562.6M-18.7% | -$550.8M | -$529.8M | -$502.5M | -$474.0M-9.8% | N/A |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
SLN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.5M+107.0% | -$15.6M-26.8% | -$17.3M+37.1% | -$10.9M+57.5% | -$21.8M-302.7% | -$12.3M-34.6% | -$27.5M | -$25.6M |
| Depreciation & Amortization | $73K-9.9% | $72K-1.4% | $77K+1.3% | $81K-5.8% | $81K-5.8% | $73K-17.0% | $76K | $86K |
| Stock-Based Compensation | N/A | $2.4M-30.9% | N/A | N/A | N/A | $3.5M-14.0% | N/A | N/A |
| Capital Expenditures | $0-100.0% | $0-100.0% | $0-100.0% | $3K-95.3% | $48K-43.5% | $4K | $62K | $64K |
| Free Cash Flow | $1.5M+107.0% | -$15.6M-26.7% | -$17.3M+37.2% | -$10.9M+57.6% | -$21.8M-297.4% | -$12.3M-34.7% | -$27.5M | -$25.7M |
| Investing Cash Flow | $64.9M+4257.5% | $10.0M+122.5% | -$53.3M-180.7% | $51.3M+234.5% | -$1.6M-3532.6% | -$44.4M+11.1% | $66.1M | -$38.1M |
| Financing Cash Flow | $2K+100.0% | $0-100.0% | $0+100.0% | $0-100.0% | $1K-99.9% | $14K-100.0% | -$98K | $8.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SLN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 97.4%+35.4pp | 64.7%-27.2pp | 59.8% | 62.1% | 62.0%-20.2pp | 92.0% | -142.9% |
| Operating Margin | N/A | -3729.2% | -36650.0% | -16505.7% | -10697.8% | -20006.3% | -17.2% | -2002.5% |
| Net Margin | N/A | -3544.3% | -34611.8% | -13181.1% | -12211.6% | -20091.5% | 48.6% | -2372.8% |
| Return on Equity | -31.9%-2.8pp | -30.3%-5.0pp | -18.9%-28.1pp | -28.3%-0.2pp | -29.0%-15.2pp | -25.3%-23.8pp | 9.2% | -28.1% |
| Return on Assets | -11.5%+5.0pp | -13.0%+2.4pp | -8.9%-15.0pp | -14.3% | -16.6% | -15.4% | 6.1% | N/A |
| Current Ratio | 7.42-2.6x | 9.83+1.0x | 8.72-2.4x | 7.69 | 10.06 | 8.81 | 11.14+6.5x | N/A |
| Debt-to-Equity | 1.77+1.0x | 1.33+0.7x | 1.11+0.6x | 0.98 | 0.75 | 0.64 | 0.51-3.9x | N/A |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.00-0.1x | 0.00 | 0.00 | 0.00 | 0.12 | N/A |
| FCF Margin | N/A | -3697.4% | -50844.1% | -6851.6% | -9746.4% | -8671.1% | -108.8% | -1713.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Silence Therapeutics Plc SLN | FY2025 | $559K | -$88.6M | N/A | $612.8M | — |
| Vor Biopharma Inc. VOR | FY2025 | N/A | -$696.0M | N/A | $1.2B | — |
| Sagimet Biosciences Inc. Series A SGMT | FY2025 | N/A | -$51.0M | N/A | $633.2M | — |
| PUMA BIOTECHNOLOGY INC PBYI | FY2025 | $228.4M | $31.1M | 13.6% | $531.2M | 69/100 |
Where Silence Therapeutics Plc Ranks
Frequently Asked Questions
What is Silence Therapeutics Plc's annual revenue?
Silence Therapeutics Plc (SLN) reported $559K in total revenue for fiscal year 2025. This represents a -98.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Silence Therapeutics Plc's revenue growing?
Silence Therapeutics Plc (SLN) revenue declined by 98.7% year-over-year, from $43.3M to $559K in fiscal year 2025.
Is Silence Therapeutics Plc profitable?
No, Silence Therapeutics Plc (SLN) reported a net income of -$88.6M in fiscal year 2025.
What is Silence Therapeutics Plc's EBITDA?
Silence Therapeutics Plc (SLN) had EBITDA of -$90.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Silence Therapeutics Plc's gross margin?
Silence Therapeutics Plc (SLN) had a gross margin of 61.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Silence Therapeutics Plc's return on equity (ROE)?
Silence Therapeutics Plc (SLN) has a return on equity of -142.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Silence Therapeutics Plc's free cash flow?
Silence Therapeutics Plc (SLN) recorded an outflow of $62.3M in free cash flow during fiscal year 2025. This represents a 8.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Silence Therapeutics Plc's operating cash flow?
Silence Therapeutics Plc (SLN) recorded an outflow of $62.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Silence Therapeutics Plc's total assets?
Silence Therapeutics Plc (SLN) had $131.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Silence Therapeutics Plc's capital expenditures?
Silence Therapeutics Plc (SLN) invested $55K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Silence Therapeutics Plc spend on research and development?
Silence Therapeutics Plc (SLN) invested $67.8M in research and development during fiscal year 2025.
What is Silence Therapeutics Plc's current ratio?
Silence Therapeutics Plc (SLN) had a current ratio of 8.72 as of fiscal year 2025, which is generally considered healthy.
What is Silence Therapeutics Plc's debt-to-equity ratio?
Silence Therapeutics Plc (SLN) had a debt-to-equity ratio of 1.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Silence Therapeutics Plc's return on assets (ROA)?
Silence Therapeutics Plc (SLN) had a return on assets of -67.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Silence Therapeutics Plc's P/E ratio?
Silence Therapeutics Plc (SLN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $612.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Silence Therapeutics Plc's price-to-sales ratio?
Silence Therapeutics Plc (SLN) trades at 996x sales, its market capitalization divided by revenue of $615K revenue, trailing 12 months to June 30, 2026. The market capitalization is $612.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Silence Therapeutics Plc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Silence Therapeutics Plc (SLN) held $85.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $62.3M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Silence Therapeutics Plc's Altman Z-Score?
Silence Therapeutics Plc (SLN) has an Altman Z-Score of -2.00, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Silence Therapeutics Plc's Piotroski F-Score?
Silence Therapeutics Plc (SLN) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Silence Therapeutics Plc's earnings high quality?
Silence Therapeutics Plc (SLN) reported a net loss of $88.6M while operations used $62.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.